Arbutus Biopharma Corp (NASDAQ:ABUS) has received a consensus recommendation of “Hold” from the nine analysts that are covering the firm, MarketBeat.com reports. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and five have given a buy rating to the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $13.80.

ABUS has been the topic of a number of analyst reports. ValuEngine downgraded shares of Arbutus Biopharma from a “hold” rating to a “sell” rating in a report on Wednesday, October 25th. Zacks Investment Research cut Arbutus Biopharma from a “hold” rating to a “sell” rating in a research note on Wednesday, January 3rd. BidaskClub cut Arbutus Biopharma from a “sell” rating to a “strong sell” rating in a research note on Thursday, December 14th. JMP Securities reiterated an “outperform” rating and set a $13.00 target price (up from $12.00) on shares of Arbutus Biopharma in a research note on Wednesday, October 4th. Finally, Leerink Swann reiterated a “market perform” rating and set a $5.00 target price (up from $4.00) on shares of Arbutus Biopharma in a research note on Tuesday, November 7th.

Institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. raised its stake in Arbutus Biopharma by 2.7% in the 2nd quarter. Vanguard Group Inc. now owns 77,413 shares of the biopharmaceutical company’s stock valued at $279,000 after acquiring an additional 2,035 shares during the period. OxFORD Asset Management LLP raised its stake in Arbutus Biopharma by 89.9% in the 2nd quarter. OxFORD Asset Management LLP now owns 83,310 shares of the biopharmaceutical company’s stock valued at $300,000 after acquiring an additional 39,436 shares during the period. Point72 Asset Management L.P. bought a new stake in Arbutus Biopharma in the 3rd quarter valued at about $1,393,000. Finally, RTW Investments LP raised its stake in Arbutus Biopharma by 1.1% in the 3rd quarter. RTW Investments LP now owns 5,266,280 shares of the biopharmaceutical company’s stock valued at $32,651,000 after acquiring an additional 56,457 shares during the period. Institutional investors and hedge funds own 59.99% of the company’s stock.

Arbutus Biopharma (NASDAQ:ABUS) traded up $0.40 on Friday, reaching $5.55. 317,178 shares of the company’s stock were exchanged, compared to its average volume of 202,785. The company has a quick ratio of 11.03, a current ratio of 11.03 and a debt-to-equity ratio of 0.08. The stock has a market cap of $302.79, a P/E ratio of -1.11 and a beta of 1.07. Arbutus Biopharma has a 1 year low of $2.35 and a 1 year high of $8.25.

Arbutus Biopharma (NASDAQ:ABUS) last posted its quarterly earnings data on Thursday, November 2nd. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.38) by $0.21. sell-side analysts forecast that Arbutus Biopharma will post -1.29 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Arbutus Biopharma Corp (ABUS) Receives $13.80 Consensus Target Price from Analysts” was first posted by Daily Political and is owned by of Daily Political. If you are reading this news story on another domain, it was stolen and reposted in violation of US & international trademark & copyright law. The original version of this news story can be accessed at https://www.dailypolitical.com/2018/01/23/arbutus-biopharma-corp-abus-receives-13-80-consensus-target-price-from-analysts.html.

About Arbutus Biopharma

Arbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, is a therapeutic solutions company. The Company is engaged in discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), a disease of the liver caused by the hepatitis B virus (HBV).

Analyst Recommendations for Arbutus Biopharma (NASDAQ:ABUS)

Receive News & Ratings for Arbutus Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arbutus Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.